Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly-soluble drug

S.T.P. Pharma Sciences

Volumn 12, Issue 2, 2002, Pages 97-101

  El Shabouri, M H ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bioavailability; Dissolution; Nanoparticles; Pharmacokinetics; Spironolactone

Indexed keywords

CANRENONE; GLYCOCHOLATE SODIUM; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POVIDONE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; EMULSION; EVAPORATION; MALE; NONHUMAN; PARTICLE SIZE;

EID: 0036223252     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Factors influencing comparative bioavailability of spironolactone tablets
2. Correlation of urinary excretion with in vitro dissolution using several dissolution methods for hydrochlorothiazide formulations
3. Enhancement of cabamazepine dissolution: In vitro and in vivo evaluation
4. Absorption of oral progesterone is influenced by vehicle and particle size
5. Non-linear assessment of nitrofurantoin bioavailability in rabbits
6. Oral versus vaginal absorption in oestradiol in postmenopausal women: Effect of different particle size
7. Dependence of area under the curve on proquazone particle size and in vitro dissolution rate
8. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone
9. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs
10. Improved oral absorption of a poorly water-soluble drug, HO-221 by wet-beed milling producing particles in submicron region
11. Indomethacin polymeric nanosuspension prepared by microfluidization
12. Aqueous nanodispersions prepared by salting-out process
13. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
14. Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior
15. Nanosuspensions for the formulation of poorly soluble drug. I. Preparation by a size-reduction technique
16. Disposition and metabolism
17. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by HPLC
18. Lyotropic paracrystalline phases obtained with ternary and quaternary systems of amphiphilic substances in water: Studies in aqueous systems of lecithin, bile salt and cholesterol
19. Ternary and quaternary aqueous systems containing bile salts, lecithin and cholesterol
20. Dissolution rate studies. II. Dissolution of particles under conditions of rapid agitation
21. Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions
22. Physico-chemical aspects of drug release. VII. The effect of surfactant concentration and particle size on solubility and dissolution rate of felodipine, a sparingly soluble drug
23. Enhancement of dissolution rate of probenecid in phospholipid coprecipitates
24. Improved dissolution of indomethacin in coprecipitates with phospholipids